Altimmune, Inc. (ALT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US02155H2004
Altimmune, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 41,000.00 USD |
| Operating income | -94.49 m USD |
| EBIT | -94.68 m USD |
| Net income | -88.09 m USD |
| Diluted EPS – continuing operations | -1.00 USD |
Full history since 2005, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
More stocks
- Xiamen R&T Plumbing Technology Co Ltd (002790.SZ)
- Beijing SunwayWorld Science & Technology Co. Ltd. (301159.SZ)
- Citi Trends Inc (CTRN)
- eQ Oyj (EQV1V.HE)
- KOSES Co.Ltd (089890.KQ)
- Boiron SA (BOI.PA)
- Daiken Biomedical Co., Ltd. (7780.TW)
- Sports Gear Co. Ltd (6768.TW)
- Guangdong PAK Corporation Co Ltd (300625.SZ)
- TIMBERLAND BANCORP INC (TSBK)
- DongGuan Winnerway Industrial Zone Ltd (000573.SZ)
- Liaoning He Eye Hospital Group Co. LTD. (301103.SZ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.